- Home
- MNOV vs MCRB Comparison
MNOV vs MCRB Comparison
Compare MNOV & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNOV
- MCRB
- Stock Information
- Founded
- MNOV 2000
- MCRB 2010
- Country
- MNOV United States
- MCRB United States
- Employees
- MNOV N/A
- MCRB N/A
- Industry
- MNOV Biotechnology: Pharmaceutical Preparations
- MCRB Biotechnology: Pharmaceutical Preparations
- Sector
- MNOV Health Care
- MCRB Health Care
- Exchange
- MNOV Nasdaq
- MCRB Nasdaq
- Market Cap
- MNOV 73.1M
- MCRB 72.4M
- IPO Year
- MNOV 2005
- MCRB 2015
- Fundamental
- Price
- MNOV $1.41
- MCRB $7.67
- Analyst Decision
- MNOV Strong Buy
- MCRB Hold
- Analyst Count
- MNOV 1
- MCRB 5
- Target Price
- MNOV $9.00
- MCRB $73.67
- AVG Volume (30 Days)
- MNOV 11.3K
- MCRB 95.5K
- Earning Date
- MNOV 05-13-2025
- MCRB 05-07-2025
- Dividend Yield
- MNOV N/A
- MCRB N/A
- EPS Growth
- MNOV N/A
- MCRB N/A
- EPS
- MNOV N/A
- MCRB 8.98
- Revenue
- MNOV N/A
- MCRB N/A
- Revenue This Year
- MNOV N/A
- MCRB N/A
- Revenue Next Year
- MNOV N/A
- MCRB N/A
- P/E Ratio
- MNOV N/A
- MCRB $0.92
- Revenue Growth
- MNOV N/A
- MCRB N/A
- 52 Week Low
- MNOV $1.12
- MCRB $6.53
- 52 Week High
- MNOV $2.55
- MCRB $30.60
- Technical
- Relative Strength Index (RSI)
- MNOV 47.13
- MCRB 42.44
- Support Level
- MNOV $1.34
- MCRB $7.32
- Resistance Level
- MNOV $1.45
- MCRB $7.69
- Average True Range (ATR)
- MNOV 0.07
- MCRB 0.72
- MACD
- MNOV -0.01
- MCRB 0.16
- Stochastic Oscillator
- MNOV 52.17
- MCRB 44.36
About MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's current strategy is to focus its development activities on therapeutics for neurological disorders and fibrotic diseases.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.